Document is current
Any future updates will be listed below
-
Authors
Avrillon, Virginie https://orcid.org/0000-0002-5508-557X
Daniel, Catherine
Boisselier, Pierre
Le Péchoux, Cécile
Chouaid, Christos
-
Funding
Funding for this research was provided by:
astrazeneca
- License Information
-
More Information
Article History
Received: 2 July 2021
Accepted: 6 January 2022
First Online: 9 February 2022
Declarations
:
: Virginie Avrillon: Consultant/Honoraria’s: BMS, Pfizer, Roche; Catherine Daniel: Consultant/ Honoraria’s: Astrazeneca, BMS, Amgen; Pierre Boisselier: Consultant/ Honoraria’s: Astrazeneca, BMS, Merck, MSD; Cécile Le Péchoux: Consultant/Honoraria’s/Grants to institution: Astrazeneca, Roche, Nanobiotix, Eli-Lilly, Medscap, PriMEOncology Amgen; Christos Chouaid: Consultant/ Honoraria’s: BMS, MSD, BI, Roche, AZ, Amgen, Eli-Lilly, Sandoz, Janssen, MundiPhaema, GSK, Sanofi, Bayer, Novartis, Takeda, Pfizer, Research project funding: BMS, BI, Roche, AZ, Amgen, Novartis, Takeda.
: This early access program cohort was requested by the French Health Authorities (ANSM) and was closely followed by them during the study conduct.
: All patients have given their consent to participate in this early access program cohort and have received an information note on the collection of their data for this early access program and have given their consent.
: All patients have received an information note on the publication of the aggregate results and have given their consent.
